Active immunization with tumor cells transduced by a novel AAV plasmid- based gene delivery system

Journal of Immunotherapy

Volumn 20, Issue 1, 1997, Pages 26-37

  Clary, Bryan M ^a   Coveney, Eamonn C ^a   Blazer III, Dan G ^a   Philip, Ramila ^b   Philip, Mohan ^b   Morse, Michael ^a   Gilboa, Eli ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Applied Immune Sciences   (United States)

Author keywords

Cytokine; Gene therapy; Tumor vaccines

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; DRUG EFFECT; DRUG EFFICACY; FOOT PAD; GENE TARGETING; GENETIC ENGINEERING; INTERFERON PRODUCTION; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LIPOSOMES; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PLASMIDS; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0031451716     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199701000-00003     Document Type: Article

References (37)

1. Hanna M, Ransom J, Pomato N, et al. Active specific immunotherapy of human colorectal carcinoma with an autologous tumor cell/bacillus Calmette-Guerin vaccine. Ann NY Acad Sci 1993;690:135-46.
2. Schirrmacher V, Schlag P, Liebrich W, Patel B, Stoeck M. Specific immunotherapy of colorectal carcinoma with Newcastle-disease virus-modified autologous tumor cells prepared from resected liver metastases. Ann NY Acad Sci 1993;690:364-6.
3. Ioannides C, Platsoucas C, O'Brian C, et al. Viral oncosylates in cancer treatment: immunological mechanisms of action. Anticancer Res 1989;9:535-44.
4. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M. Tumor inhibition by interleukin-2 at the tumor/host interface. Biochim Biophys Acta 1986;865:307-27.
5. Bubenik J, Perlmann P, Indrova M, Simova J, Jandlova T, Neuwirt J. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL2) containing preparation. Cancer Immunol Immunother 1983;14:205-6.
6. Aoki T, Tashiro K, Miyatake S, et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992;89:3850-3.
7. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 1993;177:1127-34.
8. Fearon E, Pardoll D, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 1990;60:397-403.
9. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
10. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
11. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity. Cancer Res 1990;50:7820-5.
12. Golumbek P, Lazenby A, Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
13. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
14. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-γ genes. J Immunother 1993;14:191-201.
15. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994;54:3516-20.
16. Vieweg J, Rosenthal R, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994;54:3516-20.
17. Hamaoka T, Fujiwara H. Phenotypically and functionally distinct T cell subsets in anti-tumor responses. Immunol Today 1987;8:267-9.
18. Greenberg P. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
19. Philip R, Clary B, Brunette E, et al. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin Cancer Res 1996;2:59-68.
20. Vieweg J, Boczkowski D, Roberson K, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995;55:2366-72.
21. Porgador A, Bannerji R, Watanabew Y, Feldman M, Gilboa E, Eisenbach L. Anti-metastatic vaccination of tumor-bearing mice with two types of gamma-interferon gene inserted tumor cells. J Immunol 1993;150:1458-63.
22. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
23. Littman D, Thomas V, Maddon P, Chess L, Axel R. The isolation and sequence of the gene encoding T8: a molecule defining functional classes of T-lymphocytes. Cell 1985; 40:237-46.
24. Wallach D, Fellous M, Revel M. Preferential effect of interferon-gamma on the synthesis of HLA antigens and their mRNA's in human cells. Nature 1982;299:833-5.
25. Porgador A, Gansbacher B, Bannerji R, et al. Antimetastatic vaccination of tumor bearing mice with IL-2 gene inserted tumor cells. Int J Cancer 1993;53:471-7.
26. Fearon E, Pardoll D, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 1990;60:397-403.
27. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989;86:9456-60.
28. Miller D, Adam M, Miller A. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-42.
29. Dillman R, Nayak S, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65-9.
30. Jaffee E, Dranoff G, Cohen L, et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993;53:2221-6.
31. Lewko W, Ladd P, Hubbard D, et al. Tumor acquisition, propagation, and preservation. Cancer 1989;64:1600-7.
32. McBain J, Weese J, Meisner L, Wolberg W, Willson J. Establishment and characterization of human colorectal cancer cell lines. Cancer Res 1984;44:5813-21.
33. Campling B, Haworth A, Baker H, et al. Establishment and characterization of a panel of human lung cancer cell lines. Cancer 1992;69:2064-74.
34. Wang C, Huang L. Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. Biochemistry 1989;28: 9508-14.
35. Feigner P, Gadek T, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7.
36. Nabel G, Nabel E, Yang Z, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11.
37. Philip R, Brunette E, Kilinski L, et al. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 1994;14:2411-8.